Saniona ABCHIX:SANIOS 66 EBIT per Share is kr1.74 as of Mar. 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 66/100 and a GF Value™ of kr26.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, Saniona AB ranks worse than 85324.15% on this metric.
Saniona AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.39.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.74.
During the past 12 months, the average EBIT per Share Growth Rate of Saniona AB was -17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Saniona AB's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Saniona AB was 30.80% per year. The lowest was -116.00% per year. And the median was -15.05% per year.
CHIX:SANIOs's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.35 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Saniona AB's EBIT for the
three
months ended in Mar. 2026 was kr-53.4 Mil.
Saniona AB (CHIX:SANIOs) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Saniona AB EBIT per Share Related Terms
Saniona AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Saniona AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (CHIX:SANIOS) has a EBIT per Share of kr1.74 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #999999 out of 1172 companies in the Biotechnology industry.
Is Saniona AB's EBIT per Share too high?
Saniona AB's current EBIT per Share is kr1.74. Based on the distribution chart, Saniona AB ranks #999999 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Saniona AB has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #999999 out of 1172 companies for EBIT per Share. This places Saniona AB in the lower half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Saniona AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current EBIT per Share is kr1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.73, compared to a current price of kr12.75 — trading 52.3% below its estimated fair value. The current EBIT per Share is kr1.74. Saniona AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current EBIT per Share is kr1.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.75 is trading 52.3% below its estimated GF Value™ of kr26.73.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
EBIT per Share: kr1.74
GF Value™: kr26.73 vs. price of kr12.75 (52.3% below fair value)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
66GF Score
Get the complete analysis for CHIX:SANIOS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
